153 related articles for article (PubMed ID: 12767041)
1. Codominance of cisplatin resistance in somatic cell hybrids.
Ying YL; Shen DW; Liang XJ; Gottesman MM
J Cell Physiol; 2003 Jul; 196(1):63-9. PubMed ID: 12767041
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
3. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells.
Liang XJ; Shen DW; Gottesman MM
J Inorg Biochem; 2004 Oct; 98(10):1599-606. PubMed ID: 15458822
[TBL] [Abstract][Full Text] [Related]
4. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16.
Mirakhur B; Parekh HK; Simpkins H
Cancer Res; 1996 May; 56(10):2256-62. PubMed ID: 8625294
[TBL] [Abstract][Full Text] [Related]
5. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
6. Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines.
Shen DW; Liang XJ; Gawinowicz MA; Gottesman MM
Mol Pharmacol; 2004 Oct; 66(4):789-93. PubMed ID: 15385639
[TBL] [Abstract][Full Text] [Related]
7. Differential transactivation of human metallothionein-IIa in cisplatin-resistant and -sensitive cells.
Yang YY; Robbins PD; Lazo JS
Oncol Res; 1998; 10(2):85-98. PubMed ID: 9666516
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E
Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321
[TBL] [Abstract][Full Text] [Related]
9. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
10. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake.
Shen DW; Goldenberg S; Pastan I; Gottesman MM
J Cell Physiol; 2000 Apr; 183(1):108-16. PubMed ID: 10699972
[TBL] [Abstract][Full Text] [Related]
11. [Up-regulation of human chorionic gonadotropin alpha subunit gene and human mitochondrial cytochrome c oxidase subunit II gene in cis-Diamminedichloroplatinum(II)-resistant human head and neck squamous carcinoma cells].
Higuchi E
Hokkaido Igaku Zasshi; 1999 May; 74(3):231-8. PubMed ID: 10422566
[TBL] [Abstract][Full Text] [Related]
12. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin.
Caney C; Singh G; Lukka H; Rainbow AJ
Int J Radiat Biol; 2004 Apr; 80(4):291-9. PubMed ID: 15204706
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
14. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells.
Wu ZZ; Lu HP; Chao CC
Biochem Pharmacol; 2010 Jul; 80(2):262-76. PubMed ID: 20361941
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
17. Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance.
Cimbora-Zovko T; Ambriović-Ristov A; Loncarek J; Osmak M
Eur J Pharmacol; 2007 Mar; 558(1-3):27-36. PubMed ID: 17234182
[TBL] [Abstract][Full Text] [Related]
18. Alterations in the glycoform of cisplatin-resistant human carcinoma cells are caused by defects in the endoplasmic reticulum-associated degradation system.
Nakagawa H; Ohira M; Hayashi S; Abe S; Saito S; Nagahori N; Monde K; Shinohara Y; Fujitani N; Kondo H; Akiyama S; Nakagawara A; Nishimura S
Cancer Lett; 2008 Nov; 270(2):295-301. PubMed ID: 18573595
[TBL] [Abstract][Full Text] [Related]
19. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins.
Shen D; Pastan I; Gottesman MM
Cancer Res; 1998 Jan; 58(2):268-75. PubMed ID: 9443404
[TBL] [Abstract][Full Text] [Related]
20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
